Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 14/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064627 | 1.00 | PTPN1 (0.58) | PTPN1KDM4ERAB9ANPC1HPGD | |
| SCHEMBL7065968 | 0.77 | PTPN1 (0.80) | PTPN1 | |
| SCHEMBL7065973 | 0.77 | PTPN1 (0.80) | PTPN1 | |
| SCHEMBL7064827 | 0.69 | PTPN1 (0.67) | PTPN1KDM4EHPGD | |
| SCHEMBL7064825 | 0.69 | PTPN1 (0.67) | PTPN1KDM4EHPGD | |
| SCHEMBL28339486 | 0.66 | HPGD (0.59) | KDM4ERAB9ANPC1HPGDMAPT | |
| SCHEMBL28341795 | 0.66 | HPGD (0.59) | KDM4ERAB9ANPC1HPGDMAPT | |
| SCHEMBL28341897 | 0.66 | RAB9A (0.56) | KDM4ERAB9ANPC1HPGDMAPT | |
| SCHEMBL28341779 | 0.66 | RAB9A (0.56) | KDM4ERAB9ANPC1HPGDMAPT | |
| SCHEMBL28341896 | 0.66 | RAB9A (0.56) | KDM4ERAB9ANPC1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | ABBOTT LABORATORIES | 2002-03-21 | — | — | US | claimed |
| EP-1313696-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | ABBOTT LABORATORIES | 2002-03-21 | — | — | US | disclosed |
| WO-2002018323-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | PPM1A, PTPRO, PTP4A1 | PTPN1 10/4885KDM4E 2015/4885RAB9A 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.